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Diabetic nephropathy (DN) is among the most serious complications of diabetes mellitus,
and often leads to end-stage renal disease ultimately requiring dialysis or renal transplanta-
tion. The loss of podocytes has been reported to have a role in the onset and progression of
DN. Here, we addressed the activation mechanism of Smad3 signaling in podocytes.
Expression of RII and activation of Smad3 were induced by AGE exposure (P<0.05).
Reduction of the activation of RII-Smad3 signaling ameliorated podocyte injuries in Smad3-
knockout diabetic mice. The bone morphogenetic protein 4 (BMP4) significantly regulated
activation of RII-Smad3 signalings (P<0.05). Moreover, the epithelium-specific transcription
factor, Elf3was induced by AGE stimulation and, subsequently, upregulated RII expression
in cultured podocytes. Induction of Elf3 and activation of RII-Smad3 signaling, leading to a
decrease in WT1 expression, were observed in podocytes in diabetic human kidneys. More-
over, AGE treatment induced the secretion of Elf3-containing exosomes from cultured podo-
cytes, which was dependent on the activation of the TGF-β-Smad3 signaling pathway. In
addition, exosomal Elf3 protein in urine could be measured only in urinary exosomes from
patients with DN. The appearance of urinary exosomal Elf3 protein in patients with DN sug-
gested the existence of irreversible injuries in podocytes. The rate of decline in the estimated
Glomerular Filtration Rate (eGFR) after measurement of urinary exosomal Elf3 protein lev-
els in patients with DN (R2 = 0.7259) might be useful as an early non-invasive marker for
podocyte injuries in DN.
Introduction
Diabetic nephropathy (DN) is a morbid complication associated with diabetes mellitus and is
the leading cause of end-stage renal disease (ESRD) [1]. Recent investigations have revealed
that injuries in podocytes play a critical role in the development of many glomerular diseases,
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including DN [2–4]. In addition, the involvement of podocyte loss in the progression of DN
has been reported [3–5]. Podocytes are highly specialized epithelial cells located on the surface
of the glomeruli capillaries and normally prevent leakage of proteins into urine [2, 6]. Since
these cells are unable to divide, their injury and malfunction leads to proteinuria, accumula-
tion of extracellular matrix (ECM) components, and eventually results in irreversible
glomerulosclerosis.
Various mechanisms including hyperglycemia, advanced glycation end-products (AGEs),
protein kinase C, and activation of cytokines have been proposed as the cause of DN. Hyper-
glycemia increases the expression of transforming growth factor-β (TGF-β) in glomeruli and
of matrix proteins specifically stimulated by this cytokine. TGF-β may contribute to the cellu-
lar hypertrophy and enhanced collagen synthesis observed in DN. TGF-β also plays an impor-
tant role in the AGE response of the glomeruli [7], and transgenic mice overexpressing TGF-β
develop severe glomerulosclerosis [8]. Thus, TGF-β is assumed to be a central mediator of the
sclerosing process in DN. Based on amino acid sequence homology and functional properties,
the TGF-β superfamily receptors are divided into two branches: type I and type II receptors.
First, TGF-β binds to the cell surface type II receptor (RII), forming a heterodimer capable of
recruiting and activating the type I receptor (RI). In the absence of RII, TGF-β has no affinity
for RI. This receptor/ligand complex phosphorylates the Smad3 protein, which then enters
the nucleus and regulates the transcription of a subset of genes related to cell proliferation.
However, upstream signaling transduction pathways involved in the enhancement of TGF-β
signaling in podocytes remain unknown. Transcriptional upregulation of RII is one of the
mechanisms leading to TGF-β signaling activation. Some reports demonstrated that the tran-
scription factor Elf3 interacts with purine-rich sequences in the RII promoter region [9]. How-
ever, the role of Elf3 in glomeruli has not yet been determined.
Screening for DN must be initiated at the time of type 2 diabetes diagnosis in patients, since
~7% of those have already microalbuminuria at that time [10]. DN is a progressive kidney dis-
ease caused by alterations in kidney architecture and function and constitutes one of the lead-
ing causes of ESRD. Although microalbuminuria is a widely used indicator for DN, its
diagnostic accuracy is limited by the fact that structural damages might precede albumin
excretion [11]. Therefore, it is important to find a novel diagnostic marker specific for the
detection of podocyte injuries in DN, along with the elucidation of the molecular mechanisms
leading to those injuries. Exosomes are 40–100 nm membrane vesicles secreted into the extra-
cellular space by numerous cell types. These structures can be isolated from body fluids includ-
ing urine and plasma [12]. Although exosomes were first described 30 years ago [13], these
extracellular vesicles were largely ignored, forgotten, or dismissed as a means of cellular waste
disposal. But in recent years, urinary exosomes have become an appealing source for biomark-
ers discovery as they contain molecular constituents of their cell of origin, including proteins
and genetic material, and they can be isolated in a non-invasive manner [12]. In this study, we
evaluated the significance of urinary exosomal Elf3 as a non-invasive diagnostic and predictive
biomarker in patients with DN.
Materials and methods
Animals
Animals were housed under specific pathogen-free conditions at the animal facility of Tokush-
ima University. All animal experiments were performed in accordance with the institutional
guidelines, and the Review Board of Tokushima University granted ethical permission for this
study. Six-week-old male C57BL/6 (WT), BKS/Cg-m+/+ Lepr db (db/db) and BKS/Cg-m+/+
Lepr db (db/+) mice were obtained from Charles River Japan (Tokyo, Japan) as previously
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described [14]. In the present study, we assessed Smad3+/- mice for a comparatively long
period to examine the effects of Smad3 expression and phosphorylation and to evaluate the
involvement of Smad3 in DN. Heterozygous Smad3- knockout mice were kindly provided by
Dr. Yasue, University of Tokushima. We attempted to generate Smad3-null mice using pairs
of Smad3+/- mice, but progeny was rarely obtained, and pups were fragile and could not sur-
vive for a long period (5 weeks at the most). Therefore, BKS/Cg-m+/+ Lepr db (db/db) x
Smad3+/- mice were developed using pairs of Lepr db+/- x Smad3+/-. Smad3+/-;db/+ mice were
generated by crossing Smad3+/- and db/+ mice. Moreover, Smad3+/-;db/db were generated by
crossing Smad3+/-;db/+ and db/+ mice as previously described [14]. Blood glucose concentra-
tions were measured from the tail vein (glucose assay kit; Abbott). The diabetic phenotype was
confirmed 4 weeks after birth by blood glucose>300 mg/dl.
Patients
Fifty patients with overt or heavy proteinuria and five healthy subjects were enrolled in this
study. The recruitment took place at the Department of Nephrology of the Tokushima Univer-
sity Hospital, from April 2001 until March 2015. DN (n = 25) and minimal change nephrotic
syndrome (MCNS;n = 25) were proven by renal biopsy. Type 2 diabetes mellitus was diag-
nosed according to the Japan Diabetes Society criteria. All the procedures were performed in
accordance with the guidelines of the Helsinki Declaration on Human Experimentation and
the Ethical Guidelines on Clinical Research published by the Japanese Health, Labor and Wel-
fare Ministry. This study was approved by the Ethics Committee of Tokushima University,
and informed written consent was obtained from all patients and healthy subjects as previously
described [12]. The average age at biopsy was 48.2 ± 15.9 years, and the mean follow-up time
after renal biopsy was 51.6 months (range: 7–98 months).
Histological studies
Histopathological studies were performed on human tissues. Kidney specimens (n = 50) were
obtained from renal biopsies. Kidney tissue blocks for light microscopy examination were
fixed with Dubosq-Brazil solution and embedded in paraffin. Portions of kidney slices were
mounted in Tissue-Tek OCT compound (Sakura Finetechnical, Tokyo, Japan) and snap-fro-
zen. Multiple sections were prepared and stained with periodic acid silver methenamine
(PAM) and periodic acid-Schiff’s reagent (PAS). For immunofluorescence, cryopreserved kid-
ney sections were treated as previously described [15, 16]. Sections were incubated with the
anti-podocin, anti-RII, anti-WT1 (Santa Cruz, CA), anti-pSmad3 (Cell Signaling Technology),
and anti-Elf3 (Abcam) antibodies followed by incubation with the appropriate fluorescent sec-
ondary antibodies.
Cell culture
Conditionally immortalized murine podocytes were purchased from Cell Lines Service (CLS,
Eppelheim, Germany) and were propagated under permissive condition at 33˚C, as previously
described [17]. Podocytes were grown in RPMI 1640 medium (Gibco, Invitrogen, Carlsbad,
CA, USA) containing 4 mM glutamine, 5% exosome-free fetal bovine serum (FBS), and 100
units/ml penicillin/streptomycin. Podocytes between passage 5 and 10 were cultured on plates.
Cells were passaged routinely at 80% confluence by using Accutase (Millipore, Billerica, MA),
as previously described [12]. To induce differentiation, cells were switched to 37˚C (nonper-
missive condition). To examine the expression and activation of the RII-Smad3 signaling path-
way in cultured podocytes in a diabetic condition, podocytes were treated with AGE. After a
48-h exposure to AGE or BSA (5μg/ml) at 37˚C, conditioned media were collected and
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proteins were isolated from podocytes. Equal amounts of cell lysates or conditioned media
were subjected to western blotting. Treatment with a BMP4-neutralizing antibody or control
IgG antibody (R&D Systems) was performed. AGE-BSA was prepared by the method
described previously [18].
Western blotting
Cell lysates were suspended in RIPA buffer (50mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet
P-40, 0.25% SDS, 1mM Na3VO4, 2mM EDTA, 1mM phenylmethylsulfonyl fluoride, 10 mg/ml
aprotinin) and incubated for 1 h at 4˚C. After electrophoresis, proteins were transferred onto a
nitrocellulose membrane (Hybond-ECL, GE Healthcare). Membranes were incubated with
anti-Smad3 (Abcam), pSmad3 (Cell Signaling Technology), α-tubulin, Elf3, RII, and WT1
(Santa Cruz Biotechnology) antibodies, followed by incubation with horseradish peroxidase-
conjugated secondary antibodies (GE Healthcare). The immunoreactive bands were visualized
using an ECL Western blotting detection system (GE Healthcare).
Plasmid and transfection
The full-length cDNA of Elf3 was obtained using gene-specific primers for reverse transcrip-
tion-PCR (RT-PCR) and was cloned into pcDNA3-GFP. The constructed plasmid was verified
by DNA sequencing. Cells cultured at 33 ˚C were electroporated (1x106 cells, 25 ms, 1300 V)
with 10 μg of the Elf3-expressing plasmid, using the Neon Transfection System (Invitrogen).
After transfection, cells were transferred to 37 ˚C, allowed to differentiate for 48 h, and used in
subsequent experiments. Using GFP as a reporter gene, the transfection efficiency of a popula-
tion of podocytes was determined as the percentage of cells expressing GFP in the entire
population.
Small-interfering RNA
Small-interfering RNAs (siRNAs) for Elf3 or control scrambled siRNA were purchased from
Dharmacon. Cells were electroporated (1x106 cells, 25 ms, 1300 V) with 3 μg of siRNA, using
the Neon Transfection System. Cells were then resuspended in complete RPMI medium, incu-
bated for 48 h, and used in subsequent experiments.
Urine preparation and isolation of exosome from urine and conditioned
media
Urine samples (50–150 ml) were collected from patients (before biopsy) and healthy subjects
in sterile containers and centrifuged at 300 xg, using a fixed-angle rotor for 10 min at room
temperature (within 1 hour of collection) to remove any particulate matter, including cells and
cell debris as previously described [12]. The clarified urine was stored at -80˚C before further
analysis. In addition, upon reaching near confluence, conditioned media of cultured podocytes
were collected, and differential centrifugation was performed. Conditioned media were centri-
fuged at 300 xg for 10 min, 2000 xg for 20 min, and 10,000 xg for 40 min. Cleared conditioned
media were then concentrated using a 3-kDa MWCO concentrator (Millipore) to<5ml. The
supernatants from urine and conditioned media were ultracentrifuged for 1 h at 70,000 xg
using an angled rotor (RP-65; Hitachi Koki Co, Ltd.). Pellets were resuspended in 5ml of
0.25M sucrose, 20mM HEPES-NaOH (pH 7.2) and poured carefully on top of 30ml sucrose
density gradients [2–0.25M sucrose, 20mM HEPES-NaOH (pH 7.2)] in 40 PA centrifuge tube
(329607A; Hitachi Koki Co, Ltd.). Samples were ultracentrifuged for 20h at 100,000 xg using a
swing rotor (RPS-28SA, Hitachi Koki Co, Ltd.) and fractionated to 12 2 ml samples in 5 PA
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centrifuge tubes (332245A; Hitachi Koki Co, Ltd.) by collecting from the bottom of the tube.
Fractions were diluted with 3 ml PBS and ultracentrifuged for 1 h at 200,000 xg using a swing
rotor (RPS-50-2; Hitachi Koki Co, Ltd.). Pellets were resuspended in 50μl PBS. The recovery
efficiency and purity were analyzed by silver staining and western blotting as previously
described [12].
Statistical analysis
Data are expressed as the mean ± standard error (S.E.). Statistical analysis for comparison was
performed using one-way analysis of variance followed by the Tukey’s multiple comparisons
test. P<0.05 was considered to indicate a statistically significant difference. Creatinine adjust-
ment is widely used for the estimation of 24-h urinary creatinine excretion from spot urine
samples. The distribution of the exosomal Elf3 expression levels was obtained based on the val-
ues of corrected Elf3, which were divided by the urinary creatinine concentration. For the
analysis of a correlation between exosomal Elf3 expression levels and the predictive power for
the prognosis of renal function, a correlation curve was obtained by plotting the quantification
results of the corrected Elf3 value.
Results
Reduction of expression and activity of Smad3 improves DN in mice
In Smad3+/-;db/db mice, both PAS- or PAM-positive mesangial areas and type IV collagen
expression levels were suppressed compared with those in db/db mice (Fig 1A and 1B). In dia-
betic mice, a decreased expression of podocyte-specific proteins, such as podocin [19] and
nephrin [20] was observed as previously described (Fig 1A and 1B). Moreover, glomerular
WT1 expression was significantly decreased in db/db mice compared with Smad3+/-;db/db
mice, suggesting that activation of Smad3 signalings is involved in podocyte damage. RII is a
type II receptor for TGF-family proteins and, specifically, phosphorylates Smad3. Further-
more, glomerular RII expression was decreased in Smad3+/-;db/db mice compared with that
in db/db mice (Fig 1A and 1B). We were able to detect a significant induction of RII and acti-
vation of Smad3, and decreased expression of WT1 protein in AGE-treated podocytes (Fig 1C
and 1D). As a result, phosphorylation of Smad3 was enhanced in AGE-treated podocytes. In
contrast, BSA did not phosphorylate Smad3. Additionally, expression of WT1 protein was
reduced in AGE-treated podocytes, suggesting that activation of RII-Smad3 signaling causes
podocyte injuries. These data suggest that repression of Smad3 expression in diabetic glomer-
uli attenuates DN progression.
Elf3 is induced by BMP4 in cultured podocytes
We previously demonstrated that BMP4, as well as TGF-β1, is involved in the process of glo-
merulosclerosis (16). To further elucidate the mechanism of RII expression and function in a
diabetic condition, we investigated the expression of RII in cultured podocytes treated with
TGF-β1 or BMP4. We were able to detect a significant induction of RII protein expression
upon BMP4 stimulation (Fig 2A). In contrast, activation of Smad3 was clearly observed in
TGFβ1-treated podocytes, because RII is a type II receptor for TGF-β1 and specifically phos-
phorylates Smad3 (Fig 2A). Based on these results, we examined the expression levels of Elf3 in
BMP4-treated podocytes. The induction of Elf3 by BMP4 was eminent in consistent with the
increase in RII protein levels induced by BMP4 (Fig 2B). In addition, AGE treatment also
upregulated the expression of Elf3 protein (Fig 2C). To confirm the role of BMP4 in AGE
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Fig 1. Effect of Smad3 deletion on phenotypic changes on podocytes in diabetic nephropathy. (A) Representative
photomicrographs of periodic acid-Schiff methenamine (PAM), periodic acid-Schiff staining (PAS), and immunohistochemical
staining are shown (original magnification x400). The left panels are data from normal control (CTL) mice and the middle panels are
from db/db mice (D), and the right panels are from Smad3-knockout diabetic mice (Smad3+/-;db/db mice) (S3D). (B) The
mesangial sclerotic fraction was determined in the three types of mice as the percentage of mesangial matrix area per total
glomerular surface area. All glomeruli were analyzed in each sample. The levels of Col4 (Col4a1) and RII mRNA in the glomeruli
were analyzed by qPCR and normalized to the expression of Rn18s. Regarding pSmad3 and WT1, the number of phosphorylated
Smad3- and WT1- positive nuclei were counted, and the mean values (per glomerulus) were calculated. The values are expressed as
the mean ± S.E. �P<0.05. (C) Western blot of protein extracts prepared from cultured podocytes treated with AGE or BSA (5 μg/ml)
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for 24 h. Equal amounts of cell lysates were subjected to Western blotting. One of three independent experiments is shown. α-
tubulin was used as loading control. (D) Optical densitometry of the bands in western blot. Values are expressed as the mean ± S.E.
(NS, not significant, �, p<0.05, t-test).
https://doi.org/10.1371/journal.pone.0216788.g001
Fig 2. Induction of RII in podocytes via BMP4 in a diabetic condition. (A) Effects of TGFβ1 and BMP4 on the expression of RII
and activation of Smad3 in cultured podocytes. (B) Effects of BMP4 on the expression of Elf3 in cultured podocytes. (C) Expression
of Elf3 in cultured podocytes treated with AGE or BSA (5 μg/ml) for 24 h. (D) Podocytes were treated with a neutralizing antibodies
for BMP4 (nAb) (10 μg/ml) or control normal IgG (CTL) for 24 h after a 24-h exposure to AGEs (5 μg/ml). Equal amounts of cell
lysates were subjected to western blotting. One of three independent experiments is shown. α-tubulin was used as loading control.
Quantitation of these proteins expression was assessed by quantitative PCR analysis and normalized to the expression of α-tubulin.
https://doi.org/10.1371/journal.pone.0216788.g002
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exposure in cultured podocytes, we performed an inhibition assay using a BMP4-specific
neutralizing antibody. Antibody-mediated neutralization of BMP4 markedly reduced the
expression of Elf3 and RII, and the activation of Smad3, resulting in the protection from the
decrease in WT1 expression (Fig 2D). Collectively, Elf3 is significantly induced by BMP4 and
is involved in podocyte damage through the activation of RII-Smad3 signaling in a diabetic
condition.
Elf3 plays a key role in regulating podocyte damage in DN
We investigated the association between glomerular expression of Elf3 and podocyte injuries
in patients with DN and patients with MCNS. We first observed that the number of WT1-posi-
tive podocytes was significantly reduced in patients with DN compared with the MCNS group
(Fig 3A), as previously reported [21]. Glomerular immunoreactivity for Elf3 was correlated
with the severity of sclerotic lesions in diabetic renal glomeruli, and the immunoreactive signal
was nearly absent in glomeruli of MCNS (Fig 3A). As expected, the increase in RII expression
and the activation of Smad3, as well as the decrease in WT1 expression, were observed in
patients with DN (Fig 3A and 3B). These histological observations suggest that the induction
of Elf3 is involved in podocyte injuries in DN. To further elucidate the relationship between
Elf3 and Smad3 signaling pathway in podocytes, Elf3 was overexpressed in podocytes by tran-
sient transfection of an Elf3-expression plasmid. Podocytes were successfully transfected with
the full-length mouse Elf3 cDNA together with GFP as indicated by the formation of green
fluorescent clusters (Fig 3C). The forced expression of Elf3 induced the activation of RII-S-
mad3 signaling and subsequently decreased the expression of WT1. These results suggest that
Elf3 significantly regulated WT1 expression via activation of Smad3 in podocytes indepen-
dently of the presence of a diabetic state (Fig 3D). Next we investigated whether Elf3 has these
regulatory effects on Smad3 activation and podocyte injuries upon AGE stimulation. Knock-
down of Elf3 by RNA interference suppressed RII-Smad3 signals and restored WT1 expression
in podocytes stimulated by AGE (Fig 3E). These results indicate that Elf3 plays an important
role in podocyte injuries through the activation of RII-Smad3 signaling in a diabetic
condition.
Cultured podocyte-derived Elf3 protein in exosomes in a diabetic condition
Recently, it has been reported that podocytes release exosomes into urine as a footprint of cel-
lular functional processes [22]. In addition, Elf3 is already known to be secreted in exosomes
and has been registered in the database ExoCarta (http://exocarta.ludwig.edu.au/, April 2011
version), which is specially dedicated to exosomes from various species and their components
[22]. To elucidate the mechanisms of exosome secretion from podocytes, we isolated exosomes
from conditioned media and examined the expression of Elf3 in exosomes secreted from cul-
tured podocytes subjected to AGE stimulation. We first detected tetraspanins classically used
as exosome markers (CD9, CD63, and CD81) (Fig 4A). Expression of Elf3 in exosomes from
podocytes treated with AGEs was also observed. In contrast, BSA stimulation used as control
did not induce the expression of Elf3 protein in exosomes (Fig 4A). To confirm whether the
secretion of Elf3 in exosomes is regulated by the activation of the TGF-β-Smad3 signaling
pathway, an inhibition assay using the TGF-β-neutralizing antibody was performed. Podocytes
treated with the BMP4-neutralizing antibody showed a significant reduction of Elf3 in exo-
somes obtained from conditioned media (Fig 4B and 4C). These findings suggest that BMP4
stimulates the secretion of Elf3 protein in exosomes as well as the induction of Elf3 protein in
cultured podocytes in a diabetic condition.
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Fig 3. Glomerular expression of Elf3 and Smad3 signaling-related proteins in patients with DN and with MCNS. (A)
Representative photomicrographs of periodic acid-Schiff methenamine (PASM), periodic acid-Schiff staining (PAS), and
immunohistochemical staining of Col4, Elf3, RII, pSmad3 (pS3) and WT1 are shown (original magnification: x400). The left panels
contain data from patients with DN, and the right panels show data from patients with MCNS. (B) The mesangial sclerotic fraction
in patients with DN and with MCNS was determined as the percentage of mesangial matrix area per total glomerular surface area.
Regarding pSmad3 and WT1, the number of phosphorylated Smad3- and WT1- positive nuclei was counted, and the mean values
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Urinary exosomal Elf3 protein is associated with podocyte injuries in
patients with DN
Next, we investigated whether exosomal Elf3 protein is secreted from patients with protein-
uria. First, to determine whole exosomal proteins levels in the urine, exosomes obtained from
(per glomerulus) were calculated. Values are expressed as the mean ± S.E. �P<0.05. (C) Representative immunofluorescence and
microscopic images for Elf3 (green: GFP) 48 h post-transfection. (D) Effects of overexpression of full-length Elf3 (fELF3) vector or
empty vector in cultured podocytes. (E) Control siRNA (scrambled) or siRNA specific for Elf3 were transfected into podocytes.
Ablation of Elf3 expression following siRNA knockdown in cultured podocytes was confirmed by immunocytochemistry. Equal
amounts of cell lysates were subjected to western blotting. One of three independent experiments is shown. α-tubulin was used as a
loading control. Quantitation of these proteins expression was assessed by quantitative PCR analysis, and normalized to the
expression of α-tubulin.
https://doi.org/10.1371/journal.pone.0216788.g003
Fig 4. Elf3 protein in exosome in media from cultured podocytes exposured to AGE. (A) Expression of Elf3 protein in mouse
podocytes cultured in exosome-free medium under exposure to BSA or AGE (5 μg/ml) for 48 h was monitored by western blotting.
Western blot analysis for CD63, CD81, and CD9 as exosome markers for exosomes obtained from conditioned media (mExo) from
cultured podocytes. (B) Podocytes were treated with neutralizing antibodies for BMP4 (nAb: 10 μg/ml) or control normal IgG (CTL)
for 24 h after a 24-h exposure to AGE (5 μg/ml). Equal amounts of whole cell lysates (WCL) or exosomal proteins obtained from
conditioned media (mExo) were subjected to western blotting. One of three independent experiments is shown. α-tubulin was used
as a loading control. (C) Optical densitometry of these proteins in western blot was shown. The values are expressed as the mean ±
S.E. (NS, not significant, �, p<0.05, t test).
https://doi.org/10.1371/journal.pone.0216788.g004
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patients with DN, patients with MCNS, and healthy subjects were analyzed by silver staining
(Fig 5A). The loading volume for immunoblotting was normalized to the urinary creatinine
content. The amount of exosomes obtained from patients with DN was higher than that
obtained from patients with MCNS or healthy subjects. Next, we examined whether aqua-
porin-2 (AQP2) is expressed in the exosomes from the three groups, as excretion of AQP2 in
urinary exosomes has been reported in healthy subjects who had no evidence of recent kidney
or urinary tract disease [23]. While AQP2, as well as tetraspanins, could be detected in all three
groups, by western blotting, excretion of Elf3 in urinary exosomes was restricted to the urine
obtained from patients with DN (Fig 5B). This is compatible with the fact that glomerular
Fig 5. Expression levels of Elf3 and changes in eGFR after measurement of Elf3. (A) Urinary exosomes obtained from patients
with MCNS and DN, and healthy subjects (CTL) were assayed by SDS/PAGE and visualized by silver staining. The molecular weight
marker was indicated on the left. (B) Western blotting of urinary exosomes in pooled urine samples collected from patients with DN
(n = 25) and MCNS (n = 25), and healthy subjects (CTL) (n = 5) using antibodies specific for CD63, CD81, and CD9. (C) Rate of
change in eGFR after the measurement of urinary exosomal Elf3 protein levels in the patients with DN. R2 = 0.7259.
https://doi.org/10.1371/journal.pone.0216788.g005
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expression of Elf3 protein could not be observed in patients with MCNS. Based on these
results, the clinical linkage between the elevated value of urinary exosomal Elf3 protein and the
rapid decline in kidney function was examined in patients with DN. During the follow-up
period, 20.0% (5/25) of the patients with DN developed ESRD (Fig 5C). To visualize the rela-
tionship between the corrected Elf3 value and the rate of decline in the estimated Glomerular
Filtration Rate (eGFR) in each patient with DN and its trend, a scatterplot is shown in Fig 5C.
The correlation curve with a high coefficient of determination (R2 = 0.7259) was obtained, sug-
gesting that urinary exosomal Elf3 can be a molecular marker for podocyte injuries and can
predict the decline in eGFR in the coming years.
Discussion
According to the World Health Organization, the number of people with diabetes mellitus has
risen from 108 million in 1980 to 422 million in 2014 [24]. Moreover, DN is associated with an
increased risk of adverse cardiovascular outcomes, morbidity, and mortality. Podocyte struc-
tural changes have been suggested to be involved in the pathogenesis of albuminuria in diabe-
tes. Studies in rats with reduced nephron numbers and consequent glomerular hypertrophy
have demonstrated that podocytes suffer progressive injuries when forced to cover a larger sur-
face area [25]. Thus far, some reports suggest that activation of Smad3 signaling is an impor-
tant event for podocyte injury [26, 27]. However, the precise role of Smad3 in podocytes,
including transcriptional regulatory mechanisms for the phosphorylation of Smad3 are
unclear. Because normal glomeruli exhibit steady-state Smad3 expression, we conducted a
study using Smad3+/-;db/db mice. We observed that db/db mice showed severe glomerulo-
sclerosis and the increase in Col4 expression and Smad3 activation. These changes were signif-
icantly attenuated in Smad3+/-;db/db mice. Moreover, the reduction in the number of
WT1-positive podocytes is alleviated in Smad3+/-;db/db mice compared with db/db mice,
suggesting that Smad3 activation is involved in podocyte damage in diabetes mellitus. TGF-β
directly binds to TGF-β RII, which leads to the phosphorylation of TGF-β RI. This phosphory-
lation activates the RI protein kinase, that then, phosphorylates Smad3 [28]. In Smad3+/-;db/
db mice, induction of RII expression was also significantly attenuated compared with db/db
mice. Taken together, these results suggest that induction of RII expression is an important
event in the development of DN.
We recently reported on the interplay between Smad1 and Smad3 under AGE stimulation
in the progression of DN [14]. In addition, we previously demonstrated that BMP4 plays a crit-
ical role in the initiation of DN using conditional BMP4 transgenic mice [29]. To clarify the
molecular mechanisms underlying the RII-Smad3 signaling pathway activation in podocytes,
we examined the effects of TGFβ1 and BMP4 on this pathway. Although Smad3 protein
expression levels were not changed, BMP4 significantly induced the expression of RII com-
pared with the induction with TGF-β1. On the other hand, TGFβ1 activated Smad3 in cultured
podocytes as expected. It was previously reported that RII is transcriptionally regulated by Elf3
in some cancer cell lines [30, 31]. Therefore, we investigated whether Elf3 is involved in the
regulation of RII expression in cultured podocytes. Elf3 was induced by BMP4 and regulated
the RII-Smad3 signaling pathway in podocytes treated with AGEs, suggesting that Elf3 plays
an important role in the activation of Smad3 via the induction of RII and subsequent podocyte
damage.
Ets transcription factors are expressed exclusively in tissues with a high content of epithelial
cells including skin, small intestine, colon, and kidneys. Podocytes, also called glomerular vis-
ceral epithelial cells, are terminally differentiated, highly specialized cells with a unique loca-
tion, architecture, and relevance. Among Ets transcription factors, the epithelium-specific
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transcription factor Elf3 has been reported to modulate TGF-β signaling by regulating the
transcription of RII in various cancer cells [30, 31]. In this study we first demonstrated that
Elf3 is induced in diabetic glomeruli. These results suggest that Elf3 expression is induced by
direct stress, such as high glucose and/or AGEs in podocytes. Therefore, ectopic expression of
Elf3 in podocytes may be involved in the induction of abnormal signaling, including RII-S-
mad3 axis, leading to glomerulosclerosis in diabetes mellitus.
Since it is difficult to prevent the progression of nephropathy in overt nephropathy, treat-
ment at the early phase is recommended. Podocyte damage or loss is a critical symptom pre-
senting clinically with proteinuria and subsequent glomerulosclerosis. Therefore, it has been
deemed necessary to find novel diagnostic molecular markers specific for the detection of
podocyte injuries in the initial phase of DN [7, 13], along with the elucidation of the molecular
mechanisms of the activation of TGF-β signaling in podocytes. In this study, we characterized
the association between urinary exosomal Elf3 protein and kidney function in patients with
DN. Elf3 is already registered as an exosomal protein in ExoCarta (http://exocarta.ludwig.edu.
au/, April 2011 version), a database specially dedicated to exosomes from various species and
their components [10]. As far as we know, we are the first ones identifying exosomal Elf3 pro-
tein in urine. Urinary exosomal Elf3 protein levels could discriminate DN from MCNS,
despite the same level of proteinuria. From these facts, it is speculated that induction of Elf3 in
podocytes may lead to critical phenotypic alterations coupled with irreversible damages.
Because Elf3 is a member of the Ets family of transcription factors, whose expression is
restricted to epithelial cells, and known to be involved in the regulation of epithelium-specific
gene products [24, 25], Elf3 may play an important role in the process of phenotypic alter-
ations of podocyte induced by the activation of TGF-β signals. Thus, this study proposes that
quantification of Elf3 levels in urinary exosomes may be useful for evaluating podocyte injuries
due to the activation of TGF-β signaling and that it may serve as a novel predictive marker of
podocyte loss.
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